Cargando…
Sacubitril–valsartan in heart failure and multimorbidity patients
AIMS: The poor control of symptoms in patients with advanced heart failure with reduced ejection function (HFrEF) can limit the functionality of patients. Sacubitril–valsartan, compared with enalapril, has been shown to reduce mortality and hospitalization, and nowadays, there is still little eviden...
Autores principales: | Rodil Fraile, Raquel, Malafarina, Vincenzo, Tiberio López, Gregorio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165940/ https://www.ncbi.nlm.nih.gov/pubmed/30039930 http://dx.doi.org/10.1002/ehf2.12338 |
Ejemplares similares
-
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020) -
Response to: Medical journals and editorial quality control by Erviti et al.
por: Rodil Fraile, Raquel, et al.
Publicado: (2019) -
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020) -
Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
por: Cacciatore, Francesco, et al.
Publicado: (2020) -
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction
por: Tran, Jeffrey S., et al.
Publicado: (2021)